



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention

Print Date: 5/25/21

**Title:** OD2A Technical Assistance Tracking and Assessment for Program Improvement and Impact

**Project Id:** 0900f3eb81adc70e

**Accession #:** NCIPC-OOSST-2/20/20-dc70e

**Project Contact:** Pierre Olivier Cote

**Organization:** NCIPC/DOP/PPEB/SLTATB

**Status:** **Project In Progress**

**Intended Use:** **Project Determination**

**Estimated Start Date:** 08/24/2020

**Estimated Completion Date:** 12/30/2022

**CDC/ATSDR HRPO/IRB Protocol #:**

**OMB Control #:**

## Determinations

Determination	Justification	Completed	Entered By & Role
HSC: Does NOT Require HRPO Review	Not Research / Other <i>45 CFR 46.102(l)</i> Program Evaluation Quality Assurance / Improvement	3/31/20	Angel_Karen C. (idy6) CIO HSC

PRA: PRA Applies		3/31/20	Angel_Karen C. (idy6) OMB / PRA
ICRO: Returned with No Decision		3/31/20	Zirger_Jeffrey (wtj5) ICRO Reviewer

## Description & Funding

### Description

**Priority:** Standard  
**Date Needed:** 03/05/2020  
**Determination Start Date:** 02/20/20

**Description:**

In 2019, Centers for Disease Control and Prevention (CDC), Division of Overdose Prevention (DOP), awarded funds to 66 states, territories, and localities to implement the Overdose Data to Action (OD2A) program. OD2A supports recipients' efforts to use opioid morbidity and mortality data to implement data-driven prevention and response efforts across the country. CDC contracted with ICF to develop a technical assistance (TA) hub (hereafter referred to as the OD2A TA Center) to build knowledge and strengthen the capacity of the recipients to implement and evaluate surveillance and prevention activities in their jurisdictions. The OD2A TA Center will streamline and centralize CDC's TA response. Evaluating the TA provided to OD2A recipients will ensure that recipient needs are met and that TA services result in meaningful change. The continuous monitoring and evaluation of TA provided to recipients will provide feedback to improve subsequent TA events and demonstrate the effectiveness of TA in improving recipients' capacity to implement and evaluate their programs. The evaluation for this project consists of two electronic data collection instruments (a TA Feedback Form and Annual OD2A TA Center Survey) designed to collect information about TA access, utilization, and outcomes. The TA Feedback Form will be administered on an ongoing basis to collect immediate feedback following individual TA encounters and participation in group events such as webinars and in-person trainings. The Annual OD2A TA Center Survey will be distributed one time each year to assess satisfaction with overall TA provided during the year and the extent to which TA supported the successful implementation of OD2A strategies. Survey respondents will consist of beneficiaries of TA activities including OD2A program administrators, staff, evaluators, and partners. ICF will administer and analyze the surveys. CDC will provide oversight. Surveys are included under additional documentation.

**IMS/CIO/Epi-Aid/Chemical Exposure Submission:** No  
**IMS Activation Name:** Not selected  
**Primary Priority of the Project:** Not selected  
**Secondary Priority(s) of the Project:** Not selected  
**Task Force Associated with the Response:** Not selected  
**CIO Emergency Response Name:** Not selected  
**Epi-Aid Name:** Not selected  
**Assessment of Chemical Exposure Name:** Not selected

<b>Goals/Purpose</b>	The goal of this project is to evaluate and improve the effectiveness of TA provided to OD2A program recipients. Specifically, the evaluation will gather real-time information to improve ongoing provision of TA and to demonstrate the overall success and impact of OD2A TA. This evaluation will also assist CDC with future decision making on the type and number of resources allocated for TA purposes.
<b>Objective:</b>	The information obtained through the primary data collection tools will allow TA providers to assess OD2A recipients# experience and utility of knowledge and resources gained through individual TA support, peer-to-peer sessions, and other group trainings. Additionally, data collection will inquire about further program support needs to inform and modify subsequent training and TA plans. Ultimately, the evaluation data will inform subsequent rounds of TA and allow TA providers to make necessary adjustments to the overall TA strategy for continuous quality improvement. This will ensure recipients have the support necessary to implement strategies that will improve opioid surveillance and prevention policies and practices within their communities.
<b>Does this project include interventions, services, or policy change work aimed at improving the health of groups who have been excluded or marginalized and /or decreasing disparities?:</b>	Not Selected
<b>Project does not incorporate elements of health equity science:</b>	Not Selected
<b>Measuring Disparities:</b>	Not Selected
<b>Studying Social Determinants of Health (SDOH):</b>	Not Selected
<b>Assessing Impact:</b>	Not Selected
<b>Methods to Improve Health Equity Research and Practice:</b>	Not Selected
<b>Other:</b>	Not Selected
<b>Activities or Tasks:</b>	New Collection of Information, Data, or Biospecimens
<b>Target Populations to be Included/Represented:</b>	Other - Staff from State, Territorial and Local health departments and their designees working on OD2A
<b>Tags/Keywords:</b>	In alphabetical order- Evaluation Technical Assistance, Overdose Date to Action, Overdose Prevention Technical Assistance, Overdose Surveillance Technical Assistance, Program Technical Assistance, Sub
<b>CDC's Role:</b>	Activity originated and designed by CDC staff, or conducted at the specific request of CDC, or CDC staff will approve study design and data collection as a condition of any funding provided
<b>Method Categories:</b>	Survey
<b>Methods:</b>	The evaluation consists of two web-based surveys with a series of close-ended and open-ended questions. The two web-based surveys are designed to measure TA access, utilization, and outcomes across all OD2A recipient programs. The two surveys are the TA Feedback Form and Annual OD2A TA Center Survey. The TA Feedback Form will be used to measure participant knowledge, intended application, and experience after each TA encounter (e.g., webinar, in-person event, virtual training, direct consultation). The TA Feedback Form will be administered through Survey Monkey, a web-based platform, following the close of each TA activity. Staff from funded OD2A jurisdictions that participate in the event will receive an email notification and a link with instructions for accessing the survey. Two reminder emails will be sent to nonrespondents within two weeks of the initial invitation. An annual web-based survey with respondents from all OD2A recipients will be conducted to assess satisfaction with overall TA and the extent to which TA supports informed implementation of OD2A strategies. The Annual OD2A Center Survey will be automated

for each respondent to reflect the TA that has been received or accessed by the OD2A recipient during the year. The survey will be administered to a combination of up to 10 leadership team members and staff who participated in TA activities from each recipient location. The Annual OD2A TA Center Survey will also be distributed through a Survey Monkey link emailed to participants. Respondents will have three weeks to complete the survey.

Participants in TA activities will be emailed a Survey Monkey link to participate in the TA Feedback Form after each TA event; recipient project leadership and TA participants will be emailed a SurveyMonkey link for the Annual OD2A TA Center Survey in the fall of each year. The TA Feedback Form will gather OD2A recipient feedback regarding the perceived quality and effectiveness of different types of TA activities and will take approximately 5 minutes to complete. Survey items include a mix of close-ended questions using a 5-point Likert scale (e.g. strongly agree to strongly disagree) to rate aspects of the TA provided as well as open-ended questions to gather detailed feedback about satisfaction and usefulness of the TA encounter and recommendations for improvement. In addition, the survey asks participants to indicate other TA items to address in the future. The survey closes with a few demographic items to collect the role/profession and location of the respondent. The Annual OD2A TA Hub Survey will include both qualitative and quantitative questions to understand recipient experiences with TA supports and understand how OD2A recipients are using what they learned from TA to improve or inform grant related activities. The survey will take no longer than 15 minutes to complete.

**Collection of Info, Data or Biospecimen:**

The findings from these surveys will enable CDC and program stakeholders to improve delivery of TA and guide decision-making about future TA resource allocations. To ensure results are usable, ICF will develop an Evaluation and Lessons Learned Report each year. The report will share program successes, a summary of TA activities, participants, barriers encountered, TA outcomes, and recommendations for improving TA and sustaining knowledge gains. Additional dissemination channels may include the monthly progress reports as well as potential conference presentations and/or journal articles for publications of interest to funders of public health and behavioral health programs and TA providers.

**Expected Use of Findings/Results:**

- Could Individuals potentially be identified based on Information Collected?** Yes
- Will PII be captured (including coded data)?** No
- Is an assurance of confidentiality in place or planned?** No
- Is a certificate of confidentiality in place or planned?** No
- Is there a formal written agreement prohibiting the release of identifiers?** No

**Funding**

Funding Type	Funding Title	Funding #	Original Budget Yr	# Years Award	Budget Amount
CDC Contract	Division of Overdose Prevention Technical Assistance Hub	GS00Q140ADU119	2019	4	

## HSC Review

---

### HSC Attributes

Program Evaluation	Yes
Quality Assurance / Improvement	Yes

### Regulation and Policy

---

Do you anticipate this project will be submitted to the IRB office

No

Estimated number of study participants

Population - Children

Population - Minors

Population - Prisoners

Population - Pregnant Women

Population - Emancipated Minors

Suggested level of risk to subjects Do you anticipate this project will be exempt research or non-exempt research

### Requested consent process wavers

Informed consent for adults	No Selection
Children capable of providing assent	No Selection
Parental permission	No Selection
Alteration of authorization under HIPPA Privacy Rule	No Selection

### Requested Waivers of Documentation of Informed Consent

Informed consent for adults	No Selection
-----------------------------	--------------

**Children capable of providing assent** No Selection

**Parental permission** No Selection

### **Consent process shown in an understandable language**

**Reading level has been estimated** No Selection

**Comprehension tool is provided** No Selection

**Short form is provided** No Selection

**Translation planned or performed** No Selection

**Certified translation / translator** No Selection

**Translation and back-translation to/from target language(s)** No Selection

**Other method** No Selection

### **Clinical Trial**

**Involves human participants** No Selection

**Assigned to an intervention** No Selection

**Evaluate the effect of the intervention** No Selection

**Evaluation of a health related biomedical or behavioral outcome** No Selection

**Registerable clinical trial** No Selection

### **Other Considerations**

**Exception is requested to PHS informing those bested about HIV serostatus** No Selection

**Human genetic testing is planned now or in the future** No Selection

**Involves long-term storage of identifiable biological specimens** No Selection

**Involves a drug, biologic, or device** No Selection

**Conducted under an Investigational New Drug exemption or Investigational Device Exemption** No Selection

## Institutions & Staff

---

### Institutions

Name	FWA #	FWA Exp Date	IRB Title	IRB Exp Date	Funding #
ICF Inc. and Subsidiary Organizations	FWA00002349	10/13/25	icf IRB #1	08/14/21	GS00Q140ADU119

### Staff

Staff Member	SIQT Exp. Date	CITI Biomedical Exp. Date	CITI Social & Behavioral Exp. Date	CITI Good Clinical Practice Exp. Date	Staff Role	Email	Phone	Organization
Henrietta Kuoh	02/18 /2023				Program Lead	ilq7@cdc.gov	770-488-7335	OPIOID OVERDOSE STATE SUPPORT TEAM
Pierre Olivier Cote	02/19 /2023		03/29/2022		Technical Monitor	yyc8@cdc.gov	770-488-4752	STATE & LOCAL TECHNICAL ASSISTANCE TEAM A

## Data

---

### DMP

**Proposed Data Collection Start Date:** 8/24/20  
**Proposed Data Collection End Date:** 12/30/22  
**Proposed Public Access Level:** Non-Public

*Non-Public Details:*

**Reason For Not Releasing Data:** Other - The information gathered will be used for program quality improvement purposes only.

**Public Access Justification:**

Information will be collected from stakeholders who oversee, implement, and support the program activities under OD2A, including state agency administrators, program staff, local health department staff, and evaluators. Data collection will include the TA utility, preferences, needs, and interests for the optimal delivery of TA content across a diverse group of stakeholders who are directly involved in building or sustaining opioid surveillance and prevention program activities. The information gathered will be used for quality improvement purposes only. The dataset will not be made available to the public.

**How Access Will Be Provided for Data:**

Data will not be released to the public.

**Plans for Archival and Long Term Preservation:**

The name and work email address of the individuals receiving the email with the survey link will be stored separately from the survey responses and will be destroyed after administration. The survey data will be destroyed upon project completion.

**Spatiality**

Country	State/Province	County/Region
United States	Nebraska	
United States	Montana	
United States	Missouri	
United States	Mississippi	
United States	Minnesota	
United States	Michigan	
United States	Kansas	
United States	Iowa	
United States	Indiana	
United States	Illinois	
United States	Massachusetts	
United States	Maryland	
United States	Maine	
United States	Louisiana	
United States	Idaho	
United States	New York	
United States	Hawaii	
United States	Georgia	



United States	Florida	
United States	Delaware	
United States	Connecticut	
United States	Colorado	Baltimore County
United States	California	Chicago City
United States	Arkansas	Broward County, Duval County, Palm Beach County
United States	Arizona	Riverside County, San Diego County
United States	Alaska	Maricopa County
United States	Alabama	

## Dataset

Dataset Title	Dataset Description	Data Publisher /Owner	Public Access Level	Public Access Justification	External Access URL	Download URL	Type of Data Released	Collection Start Date	Collection End Date
Dataset yet to be added...									



U.S. Department of Health and Human Services  
Centers for Disease Control and Prevention